BR112022016992A2 - Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 - Google Patents

Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2

Info

Publication number
BR112022016992A2
BR112022016992A2 BR112022016992A BR112022016992A BR112022016992A2 BR 112022016992 A2 BR112022016992 A2 BR 112022016992A2 BR 112022016992 A BR112022016992 A BR 112022016992A BR 112022016992 A BR112022016992 A BR 112022016992A BR 112022016992 A2 BR112022016992 A2 BR 112022016992A2
Authority
BR
Brazil
Prior art keywords
cov
virus
sars
vaccine based
recombinant poxvirus
Prior art date
Application number
BR112022016992A
Other languages
English (en)
Portuguese (pt)
Inventor
J Goebel Scott
Evans David
Noyce Ryan
Lederman Seth
Original Assignee
Tonix Pharma Ltd
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Ltd, Univ Alberta filed Critical Tonix Pharma Ltd
Publication of BR112022016992A2 publication Critical patent/BR112022016992A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022016992A 2020-02-26 2021-02-26 Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 BR112022016992A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062981997P 2020-02-26 2020-02-26
US202063114514P 2020-11-16 2020-11-16
PCT/US2021/020119 WO2021174142A1 (en) 2020-02-26 2021-02-26 Recombinant poxvirus based vaccine against sars-cov-2 virus

Publications (1)

Publication Number Publication Date
BR112022016992A2 true BR112022016992A2 (pt) 2022-10-25

Family

ID=75267580

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016992A BR112022016992A2 (pt) 2020-02-26 2021-02-26 Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2

Country Status (12)

Country Link
US (1) US20210260182A1 (https=)
EP (1) EP4110386A1 (https=)
JP (1) JP2023515582A (https=)
KR (1) KR20220165731A (https=)
CN (1) CN116348135A (https=)
AU (1) AU2021226592A1 (https=)
BR (1) BR112022016992A2 (https=)
CA (1) CA3173996A1 (https=)
IL (1) IL295925A (https=)
MX (1) MX2022010588A (https=)
TW (1) TWI902763B (https=)
WO (1) WO2021174142A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103231A4 (en) * 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
US12558415B2 (en) * 2020-04-14 2026-02-24 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
EP4153228A4 (en) * 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
US20230295655A1 (en) * 2020-07-31 2023-09-21 Tokyo Metropolitan Institute Of Medical Science Recombinant vaccinia virus
TW202334434A (zh) * 2021-07-21 2023-09-01 中央研究院 對抗嚴重急性呼吸道症候群冠狀病毒2型之基於痘病毒的疫苗及使用該疫苗的方法
CN113621076A (zh) * 2021-08-31 2021-11-09 南华大学 一种针对新冠病毒变异毒株Delta的融合蛋白、喷鼻式疫苗及其制备方法和应用
US20250064919A1 (en) * 2022-01-06 2025-02-27 Board Of Regents, The University Of Texas System A SARS-COV-2 Human Parainfluenza Virus Type 3-Vectored Vaccine
WO2023168286A1 (en) * 2022-03-01 2023-09-07 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
EP4316514A1 (en) * 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2
GB2624391A (en) * 2022-11-15 2024-05-22 Univ Cape Town Recombinant LSDV vectored bovine coronavirus antigen constructs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004777A (en) * 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
WO2004091524A2 (en) * 2003-04-14 2004-10-28 Acambis Inc. Respiratory virus vaccines
US8541003B2 (en) * 2003-06-20 2013-09-24 Protein Sciences Corporation Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
CN1852921A (zh) * 2003-07-21 2006-10-25 美国政府卫生及公众服务部国家卫生协会 Sars冠状病毒刺突糖蛋白的可溶性片段
WO2005028634A2 (en) * 2003-09-18 2005-03-31 Emory University Improved mva vaccines
WO2005081716A2 (en) * 2003-11-24 2005-09-09 The Johns Hopkins University DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
WO2005103259A1 (en) * 2004-04-26 2005-11-03 University Health Network Sars-cov nucleocapsid protein epitopes and uses thereof
EP1778283A2 (en) * 2004-06-30 2007-05-02 ID Biomedical Corporation of Quebec Vaccine compositions for treating coronavirus infection
JPWO2006022215A1 (ja) * 2004-08-23 2008-05-08 財団法人ヒューマンサイエンス振興財団 ＳＡＲＳ−コロナウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用
JP4665122B2 (ja) * 2004-10-08 2011-04-06 財団法人 東京都医学研究機構 組み換えウイルスおよびその用途
CN101020055B (zh) * 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
EP3045181B1 (en) * 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
WO2017047089A1 (en) * 2015-09-16 2017-03-23 Shin Nippon Biomedical Laboratories, Ltd. Vaccine compositions
JP2019535311A (ja) 2016-11-02 2019-12-12 デイビッド エバンス， 合成キメラポックスウイルス
EP3788142A4 (en) 2018-05-02 2022-04-27 Tonix Pharma Holdings Limited SYNTHETIC CHIMERIC VACCINE VIRUS
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Also Published As

Publication number Publication date
MX2022010588A (es) 2023-02-09
KR20220165731A (ko) 2022-12-15
WO2021174142A1 (en) 2021-09-02
JP2023515582A (ja) 2023-04-13
CA3173996A1 (en) 2021-09-02
AU2021226592A1 (en) 2022-09-22
CN116348135A (zh) 2023-06-27
IL295925A (en) 2022-10-01
TWI902763B (zh) 2025-11-01
EP4110386A1 (en) 2023-01-04
US20210260182A1 (en) 2021-08-26
TW202146428A (zh) 2021-12-16

Similar Documents

Publication Publication Date Title
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
CL2024000409A1 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CO2018005258A2 (es) Vacuna del virus herpes simple
MX2021003175A (es) Vacuna contra el virus de la peste porcina africana.
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
MX2016008551A (es) Moleculas artificiales de acido nucleico.
BR112017014219A2 (pt) vacinas à base de nanopartículas multivalentes
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
AR124928A2 (es) Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteína c mutada y usos de la misma
BR112015005987A2 (pt) vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína
AR065076A1 (es) Vacuna contra el papilomavirus
BRPI0821034A8 (pt) Vírus influenza b recombinante, seu uso, metodo de preparação, composição de vacina o contendo e seu gene m, bem como ácido nucléico isolado, molécula do vírus influenza m e seu uso e método para aumentar a taxa de crescimento de vírus influenza b deficiente de replicação
BR112022022859A2 (pt) Vacinas contra sars-cov-2
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
BR112023005043A2 (pt) Vacina contra covid-19 à base de piv5
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112017024283A8 (pt) Vacinas contra a dengue
CL2024000820A1 (es) Vacuna recombinante contra covid-19 para producir respuesta celular en individuos con inmunidad preexistente
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
BR112019008584A2 (pt) vacinas de mosaico para vírus de doença de pé-e-boca de sorotipo a
BR112022019647A2 (pt) Vetores para produção de partículas semelhantes a vírus e usos das mesmas
AR094912A1 (es) Vacuna contra el virus de la leucemia bovina